Skip Navigation

Randomized, Double-Blind, Phase III Study of Tucatinib or Placebo in Combination with Ado-Trastuzumab Emtansine T-DM1 For Subjects with Unresectable Locally-Advanced or Metastatic HER2+ Breast Cancer

Brief Summary

Breast Cancer

Study Type:

III Identifier:

Study #:

Start Date:
Apr 08, 2020

Full Details and Eligibility at

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below. ID: NCT03975647

View Complete Trial Details & Eligibility at